Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Currus Biologics, an Australia-based cancer immunotherapy developer spun out of Peter MacCallum Cancer Centre, has secured A$10m ($7.7m) in a funding round led by the Brandon Capital Partners-managed Medical Research Commercialisation Fund, with participation from multi-university venture fund Uniseed, according to the Australian Financial Review. Currus is the oncology research centre’s first investor-led spinout. It…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.